Gaucher Disease Type I, Inflammation, Oxidative Stress
Conditions
Brief summary
The objective of this study is to evaluate oxidative stress and/or inflammation in patients with Gaucher disease type I using a series of biomarkers and correlate with measurements of currently used diagnostic biomarkers.
Detailed description
We will determine oxidative stress and/or inflammation related biomarkers in whole blood and/or plasma in adult subjects with Gaucher disease. Fifteen milliliter blood sample will be collected during three independent visits over a period of approximately 3 months. These samples will be processed to separate plasma from red blood cells and frozen until assays are performed. Standardized immunoassay methods and LC/MS based methods will be adopted to assay a series of biomarkers in these samples. These data will be correlated with currently used diagnostic biomarkers.
Interventions
None listed
Sponsors
University of Minnesota
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. All participants must be 18 years or older. 2. All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent. 3. Individuals with Gaucher disease who are medically stable for participation in study in the opinion of the investigator. 4. GD subjects must be stable on a specific ERT and/or SRT therapy at a specific dose (for e.g. on a units/kg basis) for at least 2 years or be naïve to these therapies (no therapy for 2 years). 5. GD1 patients, who have had a change in therapy i.e. a change in dose or switch from one drug to another, can be enrolled after at least 6 months have elapsed since the change and is considered stable in the opinion of the clinician providing care to the patient. 6. All participants must not have taken antioxidants coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study.
Exclusion criteria
1. Medically unstable conditions in any group as determined by the investigators 2. Concurrent disease; medical condition; or an extenuating circumstance that, in the opinion of the investigator, might compromise subject safety, study compliance, completion of the study, or the integrity of the data collected for the study. 3. Females who are pregnant or lactating or of child-bearing age who are not using acceptable forms of contraception 4. History of asthma that is presently being treated 5. Subjects who cannot or are unwilling to have blood drawn 6. Unable to adhere to study protocol for whatever reason
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Plasma C5a Concentration | 6 months | Outcome will be reported as the change in plasma concentration of C5a (ng/ml) from baseline to 6 months in participants with Gaucher disease type 1 |
| Change in Plasma Hepcidin Concentration | 6 months | Outcome will be reported as the change in plasma concentration of hepcidin (ng/ml) from baseline to 6 months in participants with Gaucher disease type 1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Blood Glutathione Concentration | 6 months | Outcome will be reported as the change in blood concentration of glutathione (umol/g) from baseline to 6 months in participants with Gaucher disease type 1 |
| Change in Plasma Tumor Necrosis Factor (TNF)-alpha Concentration | 6 months | Outcome will be reported as the change in blood concentration of TNF-alpha (pg/ml) from baseline to 6 months in participants with Gaucher disease type 1 |
Countries
United States
Contacts
CONTACTReena Kartha, PhD
PRINCIPAL_INVESTIGATORReena Kartha, PhD
University of Minnesota
Outcome results
None listed